Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
Sexually transmitted diseases (STDs), a category of infectious diseases, encompass more than 20 different infections that spread through the exchange of bodily fluids, such as semen and blood, or through direct contact with affected areas on individuals with an STD. Also referred to as venereal diseases, STDs pose the highest risk to young women.
The detection and identification of specific viral nucleic acids from individuals exhibiting signs and symptoms of respiratory infection plays a crucial role in the diagnosis of respiratory viral infections, which is an important aspect of understanding infectious diseases.
Utilizing a Respiratory Viral Panel can enhance the diagnostic process, distinguishing these infections from other conditions, including sexually transmitted diseases.
This test is indicated as an aid in the diagnosis of specific agents of gastrointestinal illness, alongside other clinical, laboratory, and epidemiological information related to infectious diseases; however, it is not intended to monitor these infections. Additionally, the test assists in the detection and identification of acute gastroenteritis, particularly in the context of outbreaks, which can sometimes overlap with concerns regarding respiratory viral panel assessments and sexually transmitted diseases.
Designed to detect the presence of key infections associated with infectious diseases, including Hepatitis B (HBV), Hepatitis C (HCV), and HIV, our testing also covers sexually transmitted diseases. Early detection allows for timely treatment, reduces the risk of transmission, and helps protect your long-term health. With advanced genetic testing methods, including a respiratory viral panel, we provide fast, accurate, and confidential results, empowering you to take control of your well-being.
Many sexually transmitted diseases (STDs) present few or overlapping symptoms, which makes clinical diagnosis of these infectious diseases challenging and often unreliable. However, recent advancements in diagnostic testing, especially at the molecular level, have significantly improved the accuracy of detection for STDs. Consequently, laboratory investigations now play a crucial role in the definitive diagnosis of sexually transmitted diseases.
The following symptoms might present:
- Burning sensation in the urethra or pain when urinating
- Sores, bumps, rashes, warts, or blisters in the genital or anal area
- Itching, pain, redness, or swelling in the genital area
- Abnormal discharge from the vagina or penis
- Pain in the pelvic or abdominal area
- Pain, soreness, or discomfort during intercourse or bleeding after intercourse
- Persistent vaginal yeast infections
- Yellowing of the eyes and skin (jaundice)
Laboratory tests are essential for diagnosing various infectious diseases, including sexually transmitted diseases (STDs). Below are some common types of STDs: Bacterial Vaginosis (BV), Chlamydia, Gonorrhea, Hepatitis (Viral Hepatitis), Herpes, HIV/AIDS, Human Papillomavirus (HPV) Infection, Mycoplasma Genitalium (Mgen), Pelvic Inflammatory Disease (PID), Syphilis, Trichomoniasis, Chancroid, and Scabies. Additionally, a Respiratory Viral Panel is used to identify respiratory infections, highlighting the importance of laboratory testing in the diagnosis of both STDs and other infectious diseases.
Be treated to reduce the risk of transmitting sexually transmitted diseases (STDs) to another person. If breastfeeding, discuss with a doctor the possible risk of transmission in breast milk and whether commercial formula should be substituted. Notify your spouse and urge them to get a checkup for infectious diseases. Follow the doctor’s orders and complete the full course of medication prescribed. Follow-up with a test to ensure that the infection has been cured. Avoid all sexual activity while being treated for an STD.
The respiratory viral panel is essential for the detection of various respiratory viruses, which are critical in the study of infectious diseases. This panel includes tests for: Covid-19, MERS, Adenovirus, Influenza A, Influenza A Subtypes H1, Influenza A Subtypes H3, Influenza B, Parainfluenza 1, Parainfluenza 2, Parainfluenza 3, Rhinovirus/Enterovirus, Metapneumovirus, Respiratory Syncytial Virus Subtype A, and Respiratory Syncytial Virus Subtype B. It is important to note that the results from this respiratory viral panel should be interpreted alongside other clinical and laboratory findings, especially when evaluating for potential sexually transmitted diseases.
Acute diarrhea caused by bacterial and viral infections represents a significant worldwide healthcare burden, particularly in the realm of infectious diseases. The Verigene® Enteric Pathogens Nucleic Acid Test (EP) is a multiplexed, qualitative test for the simultaneous detection and identification of common pathogenic enteric bacteria, viruses, and genetic virulence markers from liquid or soft stool preserved in Cary-Blair medium, collected from individuals exhibiting signs and symptoms of gastrointestinal infection. This test is essential for diagnosing various gastro viruses, including pathogens that may also be relevant in discussions surrounding respiratory viral panels and sexually transmitted diseases.
The gastrointestinal pathogen panel is used for the detection of many gastro viruses including:
- Campylobacter Group
- Salmonella Species
- Shigella Species
- Vibrio Group
- Yersinia enterocolitica
- Shiga toxin 1
- Shiga toxin 2
- Norovirus GI/GII
- Rotavirus A
This test is intended for use in conjunction with clinical presentation and other laboratory markers for the clinical management of patients with chronic HBV infection undergoing antiviral therapy. This is particularly relevant in the field of infectious diseases, where monitoring viral load is crucial. The test can be used to measure HBV DNA levels at baseline and during treatment to aid in assessing response to treatment.
The cobas® HBV Test is not intended for use as a screening test for the presence of HBV in blood or blood products or as a diagnostic test to confirm the presence of HBV infection, similar to how a Respiratory Viral Panel or tests for sexually transmitted diseases are utilized for different infections.
Reportable range is 10 to 1,000,000,000 IU/mL (1.00 to 9.00 Log IU/mL).
Clinical Significance: This test is useful in monitoring therapy and/or disease progression for various conditions, including Infectious Diseases. It is particularly relevant in the context of a Respiratory Viral Panel and can also aid in the detection of Sexually Transmitted Diseases. The reportable range is 15 to 100,000,000 IU/mL (1.18-8.00 log IU/mL).
Clinical Significance: This test is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HIV-1 infected patients. It plays a crucial role in the field of infectious diseases. The test can be used to assess patient prognosis by measuring the baseline HIV-1 RNA level or to monitor the effects of antiretroviral therapy by measuring changes in EDTA plasma HIV-1 RNA levels during the course of antiretroviral treatment. This is particularly important, as it helps healthcare providers manage patients with sexually transmitted diseases effectively, alongside other relevant testing such as the respiratory viral panel. Alternative Name(s): HIV-1 RNA, QN, PCR, Viral Load, HIV, HIV Viral Load.